L-Methylfolate Calcium Supplementation in Adolescents and Children: A Retrospective Analysis

Prior research has shown that l-methylfolate can be a safe and beneficial therapy for certain neuropsychiatric conditions in adults, such as major depressive disorder and schizophrenia. However, limited data exists on its use in children and adolescents. While it was already known that folate metabolism plays a role in brain function, the specific effects and safety of l-methylfolate in younger populations remained unclear. No prior work had resolved how l-methylfolate calcium might be used in pediatric settings. That uncertainty drove the need for a real-world assessment of its safety and patient experience in this age group. This gap motivated researchers to explore the outcomes of l-methylfolate calcium use in a clinical pediatric psychiatry setting. Prior studies had not addressed the frequency of adverse events or subjective patient responses in this demographic. Researchers wanted to determine if the benefits observed in adults could be replicated in younger patients. This study aimed to fill that knowledge gap by analyzing a retrospective dataset of pediatric and adolescent patients.

The aim of this study was to evaluate the safety and patient experience associated with l-methylfolate calcium in a pediatric and adolescent population. Researchers sought to determine if the positive outcomes seen in adult studies could be observed in younger patients. The specific problem addressed was the lack of evidence on l-methylfolate calcium use in children and adolescents with neuropsychiatric conditions. This motivated the retrospective chart review to gather real-world data on its use. The study aimed to assess the frequency of adverse events and subjective patient responses. Researchers also wanted to compare treated patients with those who were prescribed but not administered the supplement. The motivation stemmed from the need to guide clinical practice in pediatric psychiatry. This study aimed to provide evidence to support or caution against the use of l-methylfolate calcium in this age group.

Researchers conducted a retrospective chart review of patients aged 7 to 20 years who were prescribed l-methylfolate calcium at a psychiatry clinic in Amherst, NY. The study period spanned from January 1, 2010, to November 10, 2015. Patients receiving 15 mg/d (n=139) or 7.5 mg/d (n=7) of l-methylfolate calcium were identified. A comparator group of 44 patients who were prescribed but not administered the supplement was also included. Researchers analyzed common neuropsychiatric diagnoses in both groups. They also reviewed the frequency of concurrent medication use, such as antidepressants and mood stabilizers. Adverse events and laboratory abnormalities were compared between the treated and comparator populations. Subjective patient experiences were collected through self-reported outcomes in the medical records.

Adverse events occurred less frequently in the treated population compared to the comparator group (10% vs. 25%, P=0.02). The most common adverse events in the treated group were impaired sleep (5 patients) and increased anxiety (3 patients). Laboratory abnormalities did not differ significantly between the two groups (P=0.13). Positive subjective treatment experiences were reported by 22.5% of treated patients. Negative subjective experiences were reported by 5.4% of treated patients. Common diagnoses in the treated group included anxiety disorders (68%) and mood disorders (57%). In the comparator group, anxiety disorders were reported in 50% of patients and mood disorders in 52%. Antidepressants were used in 69% of the treated group and 55% of the comparator group. Mood stabilizers or antiepileptic drugs were also frequently prescribed in both groups (63% vs. 57%).

L-methylfolate calcium was well-tolerated in a pediatric and adolescent population according to the authors. The study suggests that it may provide benefits for patients with a range of neuropsychiatric conditions. The authors propose that the lower rate of adverse events in the treated group may be due to the addition of l-methylfolate calcium. Positive subjective experiences were reported by 22.5% of treated patients. Negative experiences were reported by 5.4% of treated patients. The authors note that laboratory abnormalities did not differ significantly between the groups. The study does not claim that l-methylfolate calcium is essential for treating these conditions. The authors suggest that further research is needed to confirm these findings in larger or more diverse populations. The results may inform clinical decisions regarding the use of l-methylfolate calcium in pediatric psychiatry.